Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 5/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.35 |
| ▸ | GCK | P35557 | 3/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 2/20 | 0.32 |
| ▸ | FLT4 | P35916 | 2/20 | 0.32 |
| ▸ | BMP4 | P12644 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745780 | 0.94 | CAMKK2 (0.41) | CAMKK2KDRFYNBRD4MAOB | |
| SCHEMBL13746535 | 0.91 | CAMKK2 (0.41) | CAMKK2KDRFYNBRD4 | |
| SCHEMBL13746271 | 0.91 | CAMKK2 (0.37) | CAMKK2FYNBRD4MAOB | |
| SCHEMBL13745719 | 0.90 | CAMKK2 (0.40) | CAMKK2KDRFYNBRD4MAOB | |
| SCHEMBL13745678 | 0.89 | CAMKK2 (0.35) | CAMKK2FYNBRD4MAOB | |
| SCHEMBL13746204 | 0.89 | KDR (0.41) | CAMKK2KDRFYNPTPN11BRD4 | |
| SCHEMBL13745724 | 0.88 | GRM5 (0.40) | CAMKK2KDRFYNGCKBRD4 | |
| SCHEMBL13745736 | 0.87 | CAMKK2 (0.55) | CAMKK2PTPN11 | |
| SCHEMBL13745855 | 0.87 | CAMKK2 (0.36) | CAMKK2FYNBRD4 | |
| SCHEMBL13746567 | 0.87 | CAMKK2 (0.40) | CAMKK2FYNBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | CAMKK2 94/4885KDR 3757/4885FYN 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.